Neonatal ICU therapy: a literature review on pharmacotherapies
DOI:
https://doi.org/10.34117/bjdv9n9-057Keywords:
neonatology, drug therapy, off-label use, intensive careAbstract
INTRODUCTION: The neonatal period is an age group of vulnerability, which is subject to adverse effects related to conventional drug treatments and therapies, many drugs are empirically applied in the neonatal ICU (NICU), in off-label or non-licensed ways, currently the scientific basis on pediatric pharmacological assistance is scarce, constituting an unpredictable scenario of adverse and severe drug reactions. OBJECTIVE: To analyze the main pharmacological practices in the neonatal ICU, observing the possible effects on the newborn patient. METHODOLOGY: literature review that used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) methodology. The search for articles was carried out in PubMed, SciELO and LILACS databases, applying descriptors from Descritores em Ciências da Saúde (DeCS) and Medical Subject Headings (MeSH). RESULTS: 415 articles were found and 26 were included in the study. It was noted that there is a high prevalence of overdoses and unnecessary prolongation of antibiotic therapy, adverse effects linked to bacterial resistance and alteration of the newborn’s (NB) microbiota may occur, generally these drugs were used in the scenario of neonatal sepsis and in an off-label way, vancomycin stood out as the most widely used antibiotic among the studies. The NB’s respiratory problems were pharmacologically treated with exogenous surfactant, propofol, hydrocortisone and milrinone, the clinical situations of use include Respiratory Distress Syndrome in Neonates and sedation for intubation. Painful procedures are common in the NICU, requiring pharmacological measures such as the use of analgesics and sedatives, including fentanyl, morphine, dipyrone, non-steroidal anti-inflammatory drugs and benzodiazepines, the safe application is also difficulty with these medications. Local anesthetics, such as lidocaine, are the most used for surgical pain, epidural anesthesia helps to reduce surgical stress, and topical anesthetics are useful for pain caused by skin barrier rupture. The group of drugs most used in an off-label way, according to the Anatomic Therapeutic Chemical (ATC) classification, were the group of anti-infectives for systemic use and drugs that act on the nervous system. CONCLUSION: the need for more scientific depth in the context of pharmacology at the NICU became extremely explicit during the study’s development, the lack of consensus for appropriate medical prescriptions leads to the need for greater care when prescribing for neonates, considering the inherent characteristics of the organism of these patients that alter the pharmacokinetics and pharmacodynamics of medications.
References
MacDonald MG, Seshia MMK. Avery neonatologia, fisiopatologia e tratamento do recém nascido. 7ª ed. Rio de Janeiro: Guanabara Koogan, 2018.
THIESEN, Signe et al. Incidence, characteristics and risk factors of adverse drug reactions in hospitalized children–a prospective observational cohort study of 6,601 admissions. BMC medicine, v. 11, n. 1, p. 1-10, 2013. https://doi.org/10.1186/1741-7015-11-237
NOBRE, Patricia Fernandes da Silva. Prescrição Off-Label no Brasil e nos EUA: aspectos legais e paradoxos. Ciência & Saúde Coletiva, v. 18, p. 847-854, 2013. https://doi.org/10.1590/S1413-81232013000300030
KOSZMA, Erica Inez Alves et al. Use of off-label medications in a neonatal intensive care unit. Revista Paulista de Pediatria, v. 39, 2021. https://doi.org/10.1590/1984-0462/2021/39/2020063
Jiménez E, Valls N, Astudillo P, Valls C, Cavada G, Sandoval A, et al. Evaluación del consumo de antimicrobianos en una Unidad de Neonatología: un trabajo en equipo para promover el uso racional de antimicrobianos. Rev Chilena Infectol 2017; 34 (6): 544-552. http://dx.doi.org/10.4067/S0716-10182017000600544
Rueda MS, Calderon-Anyosa R, Gonzales J, Turin CG, Zea-Vera A, Zegarra J, et al. Antibiotic Overuse in Premature Low Birth Weight Infantas in a Developing Country. Pediatr Infect Dis J 2019;38:302–307. https://doi.org/10.1097/inf.0000000000002055
Nunes BM, Xavier TC, Martins RR. Problemas relacionados a medicamentos antimicrobianos em unidade de terapia intensiva neonatal. Rev Bras Ter Intensiva. 2017;29(3):331-336. https://doi.org/10.5935/0103-507X.20170040
Ting JY, Roberts A, Tilley P, Robinson JL, Dunn MS, Paquette V, et al. Development of a national neonatal intensive care unit-specific antimicrobial stewardship programme in Canada: protocol for a cohort study. BMJ Open 2020;10:e043403. https://doi.org/10.1136/bmjopen-2020-043403
Lutsar I, Chazallon C, Trajofer U, Cabre VM, Auriti C, bertaina C, et al. Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): A randomised controlled trial. PLoS ONE 15(3): e0229380. https://doi.org/10.1371/journal.pone.0229380
Jacqz-Aigrain E, Zhao W, Sharland M, van den Anker JN. Use of antibacterial agents in the neonate: 50 years of experience with vancomycin administration. Seminars in Fetal and Neonatal Medicine. 2013; 18(1):28-34. https://doi.org/10.1016/j.siny.2012.10.003
Okasaki R, de Carvalho WB, Ceccon MEJR. Recém-nascidos com sepse por Estafilococos aureus e coagulasa-negativo tratados com Vancomicina, após aumento do nível sérico no vale. J Hum Growth Dev. 2018; 28(1):9-17. http://dx.doi.org/10.7322/jhgd.143846
Hicks RW, Hernandez J. Perioperative Pharmacology: A Focus on Vancomycin. AORN Journal. 2011; 93(5):593-99. https://doi.org/10.1016/j.aorn.2010.09.031
Mulubwa M, Griesel HÁ, Mugabo P, Dippenaar R, van Wyk L. Assessment of Vancomycin Pharmacokinetics and Dose Regimen Optimisation in Preterm Neonates. Drugs in R&D. 2020; 20:105-13. https://doi.org/10.1007/s40268-020-00302-7
Romanelli RMC, Anchieta LM, e Silva ACB, de Jesus LA, Rosado V, Clemente WT. Empirical antimicrobial therapy for late-onset sepsis in a neonatal unit with high prevalence of coagulase-negative Staphylococcus. J Pediatr. 2016; 92(5):472-8. https://doi.org/10.1016/j.jped.2016.01.008
Domaracki BE, Evans AM, Venezia RA. Vancomycin and Oxacillin Synergy for Methicillin-Resistant Staphylococci. Antimicrobial Agents and Chemotherapy. 2000; 44(5)1394-6. https://doi.org/10.1128%2Faac.44.5.1394-1396.2000
Werth BJ, Vidaillac C, Murray KP, Newton KL, Sakoulas G, Nonejuie P, Pogliano J, Rybak MJ. Novel Combinations of Vancomycin plus Ceftaroline or Oxacillin against Methicillin-Resistant Vancomycin-Intermediate Staphylococcus aureus (VISA) and Heterogeneous VISA. Antimicrobial Agents and Chemotherapy. 2013; 57(5):2376-9. https://doi.org/10.1128%2FAAC.02354-12
Kimland E, Odlind V. Off-Label Drug Use in Pediatric Patients. Clinical Pharmacology & Therapeutics. 2012; 91(5): 796-801. https://doi.org/10.1038/clpt.2012.26
LESSA, Ceane Cunha Rios et al. Prevalence and factors associated with surfactant use in Brazilian Neonatal Intensive Care Units: A multilevel analysis. Ciência & Saúde Coletiva, v. 23, p. 3067-3076, 2018. https://doi.org/10.1590/1413-81232018239.22192016
ROJAS‐REYES, Maria Ximena; MORLEY, Colin J.; SOLL, Roger. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database of Systematic Reviews, n. 3, 2012. https://doi.org/10.1002/14651858.cd000510.pub2
DE KORT, Ellen HM et al. Propofol for endotracheal intubation in neonates: a dose-finding trial. Archives of Disease in Childhood-Fetal and Neonatal Edition. v. 105, n. 5, p. 489-495, 2020. https://doi.org/10.1136/archdischild-2019-318474
Onland W, Cools F, Kroon A, et al. Effect of Hydrocortisone Therapy Initiated 7 to 14 Days After Birth on Mortality or Bronchopulmonary Dysplasia Among Very Preterm Infants Receiving Mechanical Ventilation: A Randomized Clinical Trial. JAMA. 2019;321(4):354-63. https://doi.org/10.1001/jama.2018.21443
Giaccone A, et al. Milrinone Pharmacokinetics and Pharmacodynamics in Neonates with Persistent Pulmonary Hypertension of the Newborn. Am. J. Perinatol. 2017; 34(8): 749-58. https://doi.org/10.1055/s-0036-1597996
Cruz MD, Fernandes AM, Oliveira CR. Epidemiology of painful procedures performed in neonates: a systematic review of observational studies. Eur J Pain. 2016;20(4):489-98. https://doi.org/10.1002/ejp.757
Maciel HIA, Costa MF, Costa ACL, Marcatto JO, Manzo BF, Bueno M. Medidas farmacológicas e não farmacológicas de controle e tratamento da dor em recém-nascidos. Rev. bras. ter. intensiva. 2019; 31(1): 21-6. https://doi.org/10.5935/0103-507X.20190007
KEELS, Erin et al. Prevention and management of procedural pain in the neonate: an update. Pediatrics, v. 137, n. 2, 2016. https://doi.org/10.1542/peds.2015-4271
Perry MA, Tan Z, Chen J, Weidig T, Xu W, Cong XS. Neonatal Pain: Perceptions and Current Practice. Crit Care Nurs Clin North Am. 2018; 30(4): 549-61. https://doi.org/10.1016/j.cnc.2018.07.013
HALL, R. Whit; SHBAROU, Rolla M. Drugs of choice for sedation and analgesia in the neonatal ICU. Clinics in perinatology, v. 36, n. 2, p. 215-226, 2009. https://doi.org/10.1016%2Fj.clp.2008.09.007
Bhalla T, Shepherd E, Tobias JD. Neonatal pain management. Saudi J Anaesth. 2014; 8(Suppl 1):S89–97. [PubMed: 25538531]. https://doi.org/10.4103/1658-354x.144085
Lönnqvist PA. Regional anesthesia and analgesia in the neonate. Best Pract Res Clin Anaesthesiol. 2010; 24(3):309–321. [PubMed: 21033009]. https://doi.org/10.1016/j.bpa.2010.02.012
Krishnan L. Pain relief in neonates. J Neonatal Surg. 2013; 2(2):19. [PubMed: 26023439]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4420379/
Kraychete DC, Siqueira JT, Garcia JB; Specialists Group. Recommendations for the use of opioids in Brazil: Part II. Use in children and the elderly. Rev Dor. 2014;15(1):65-9. https://doi.org/10.5935/1806-0013.20140015
Gonçalves ACS, Reis AMM, Marçal ACG, Bouzada MCF. Use of unlicensed and off-label drugs in neonates in a Brazilian university hospital. Braz. J. Pharm. Sci. 2017; 53(3): e00252. https://doi.org/10.1590/s2175-97902017000300252
Vieira VC, Costa RS, Lima RCG, Queiroz DB, de Medeiros DS. Prescrição de medicamentos off-label e sem licença para prematuros de unidade de terapia intensiva neonatal. Rev. bras. ter. intensiva. 2021; 33(2): 266-75. https://doi.org/10.5935/0103-507X.20210034
Fabretti SC, Brassica SC, Cianciarullo MA, Romano-Lieber NS. Rastreadores para a busca ativa de eventos adversos a medicamentos em recém-nascidos. Cad. Saúde Pública. 2018; 34(9): e00069817. https://doi.org/10.1590/0102-311X00069817
Agência Nacional de Vigilância Sanitária. Farmacovigilância. 2009. Disponível em: https://www.gov.br/anvisa/pt-br/assuntos/fiscalizacao-e-monitoramento/farmacovigilancia
Guzzo GM, de Magalhães AMM, de Moura GMSS, Wegner W. Segurança da terapia medicamentosa em neonatologia: olhar da enfermagem na perspectiva do pensamento ecológico restaurativo. Texto contexto - enferm. 2018; 27(3): e4500016. https://doi.org/10.1590/0104-070720180004500016

